IPBronch.com | Interventional Pulmonology

🎯 Background & Rationale

HER2 (ERBB2) mutations are identified in approximately 2–4% of non-small cell lung cancer (NSCLC) cases. Historically, these patients have had limited therapeutic options, as traditional EGFR tyrosine kinase inhibitors (TKIs) show poor efficacy. This review addresses the clinical gap in managing this specific molecular subset, focusing on the transition from chemotherapy-based regimens to targeted antibody-drug conjugates (ADCs) and novel TKI inhibitors.

👥 Study Design & Population

This publication is a narrative review summarizing the current landscape of targeted therapies for patients with HER2-mutant NSCLC. The population includes patients with advanced or metastatic NSCLC harboring HER2-activating mutations (most commonly exon 20 insertions).

📈 Methodology & Rigor

As a review article, the methodology involves a synthesis of existing clinical trial data (including Phase I/II trials like DESTINY-Lung01 and 02). The rigor is assessed based on the inclusion of landmark studies that have shaped current NCCN and ESMO guidelines for HER2-mutant disease.

🔬 Key Findings [or Planned Endpoints]

Trastuzumab Deruxtecan (T-DXd): The review highlights T-DXd as the current standard of care for pre-treated HER2-mutant NSCLC, citing significant objective response rates (ORR) and durable clinical benefit observed in clinical trials.
TKI Development: The review discusses the evolution of TKIs (e.g., pyrotinib, poziotinib) and their challenges regarding toxicity profiles and intracranial efficacy compared to ADCs.
Resistance Mechanisms: The authors identify emerging resistance patterns, such as HER2 expression loss or secondary mutations, which remain a critical area of ongoing investigation.

⚖️ Critical Appraisal

The review provides a comprehensive overview of the therapeutic shift in HER2-mutant NSCLC. However, as a narrative review, it lacks the systematic rigor of a meta-analysis. The primary limitation is the rapid evolution of the field; data regarding newer ADCs and combination strategies are constantly emerging, which may render some sections of the review quickly outdated. The external validity is high, as the findings are directly applicable to current thoracic oncology practice.

💡 The Clinical Bottom Line

For the interventional pulmonologist, the takeaway is twofold:

Tissue Acquisition: Given the necessity of identifying HER2 mutations to guide therapy, high-quality tissue sampling (via EBUS-TBNA or navigational bronchoscopy) is paramount. Sufficient tumor cellularity is required for comprehensive NGS panels that include HER2.
Clinical Context: While the interventionalist is primarily involved in diagnosis and staging, understanding that these patients are candidates for potent ADCs (like T-DXd) is vital. These agents carry a risk of interstitial lung disease (ILD)/pneumonitis, a critical adverse event that the pulmonologist must be prepared to diagnose and manage in patients presenting with new respiratory symptoms during treatment.

Original Abstract

HER2-mutant lung cancer represents approximately 2-5% of all NSCLCs and is associated with poor prognosis. Two different HER2-targeted therapeutic approaches with different mechanisms of action -antibody-drug conjugates (ADCs) and HER2-selective tyrosine-kinase inhibitors (TKIs)- have shown convincing efficacy in pretreated patients. Trastuzumab deruxtecan (T-DXd) was the first targeted therapy approved for patients with HER2-mutant NSCLC, demonstrating robust and durable responses in about 50% of these patients. Toxicity, while overall manageable, includes an increased risk of interstitial lung disease (ILD), which can be problematic and requires close clinical monitoring. More novel HER2-directed ADCs have confirmed the solid efficacy in this tumor type, showing variable rates of ILD as a class effect of these agents. On the other hand, novel orally available TKIs with higher specificity and inhibitory potency against HER2 over wild type EGFR such as sevabertinib (a dual HER2/EGFR mutant-selective reversible TKI) or zongertinib (an irreversible HER2-selective TKI that spares EGFR, including mutant EGFR) have further demonstrated deep and durable responses in this disease. Toxicities with these agents are mostly related to EGFR wild type inhibition, with significantly lower rates of ILD. Consistent with its selectivity and mechanism of action, zongertinib offers a favorable tolerability profile, with mainly low-grade adverse events including those related to wild type EGFR inhibition. In this review, we first describe the molecular landscape and clinical features of HER2-mutant NSCLC. Then, we summarize the clinical and preclinical evidence of HER2-targeted therapies and provide a forward-looking perspective of the treatment landscape of HER2-mutant NSCLC.